` AB (AB Science SA) vs DAX Index Comparison - Alpha Spread

AB
vs
D
DAX Index

Over the past 12 months, AB has underperformed DAX Index, delivering a return of -9% compared to the DAX Index's +25% growth.

Stocks Performance
AB vs DAX Index

Loading
AB
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
AB vs DAX Index

Loading
AB
DAX Index
Difference
www.alphaspread.com

Performance By Year
AB vs DAX Index

Loading
AB
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
AB Science SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

AB Science SA
Glance View

Market Cap
97.9m EUR
Industry
Pharmaceuticals

AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. The company is headquartered in Paris, Ile-De-France and currently employs 96 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

AB Intrinsic Value
0.06 EUR
Overvaluation 96%
Intrinsic Value
Price
Back to Top